The disclosure features methods that are useful for treatment of a subject having a lungdisease or disorder. In particular, methods for treating lung diseases or disorders involving the administration of N-cadherin antagonists are disclosed herein.
Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
The present invention relates, in part, to the use of dendritic cell-tumor fusion vaccines and a Bcl-2 inhibitor (e.g., venetoclax) to treat or prevent certain cancers.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds in combination with immunotherapy and chemotherapy to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity, and wherein the disease comprising cancer. Further disclosed are different type of cancers that can be treated using the methods.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Methods and products for the identification and detection of new pancreatic cancer biomarkers based on proteins in biofluids, such as plasma and serum extracellular vesicles.
Provided herein are compositions and methods for treating cardiotoxicity in a subject. The compositions and methods provided herein may, for example, be used to characterize the risk of cardiotoxicity in a subject in need of anthracycline treatment. In particular, the treatments provided herein may be applicable to subjects with breast cancer or a hematologic malignancy.
Provided herein are methods of preventing, suppressing, or treating cancer cachexia in a subject as well as methods of prolonging survival of a subject in need of cancer cachexia treatment. Such methods include administering an inhibitor of soluble epoxide hydrolase (sEH).
Artificial intelligence enabled disease profiling is described. An electrocardiogram analysis module is configured to derive disease vectors for a plurality of diseases using electrocardiogram training data from both disease-negative and disease-positive individuals. A standardized input is generated, via a data preprocessor of the electrocardiogram analysis module, from an electrocardiogram recorded from an individual. The standardized input is encoded, by a deep learning autoencoder of the electrocardiogram analysis module, into an embedding, the embedding being a lower-dimensional latent space representation of features extracted from the standardized input. At least one disease risk score for the individual is generated, by a statistical modeling algorithm of the electrocardiogram analysis module, for the plurality of diseases based on the embedding and the disease vectors.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
9.
METHODS OF IDENTIFYING AND TREATING LIVER DISORDERS
Featured are methods of identifying (e.g., diagnosing) and/or treating a subject having or at risk of developing a liver disorder, such as liver steatosis, liver fibrosis, liver cirrhosis, and/or liver cancer (e.g., HCC). The methods utilize predictive and/or diagnostic biomarkers for identifying a subject as having or having a risk of a liver disorder. The predictive and/or diagnostic biomarkers described herein can also be used to monitor the status of a subject determined to have liver disorder or a risk thereof during treatment with a liver therapy. Also disclosed are methods of treating a subject determined to have a liver disorder (e.g., liver cancer, such as HCC) or a risk thereof (e.g., by assessing the level of one or more of the disclosed biomarkers by administering a liver therapy to the subject.
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (USA)
YALE UNIVERSITY (USA)
THE UNIVERSITY OF CHICAGO (USA)
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (USA)
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (USA)
Inventor
Clementz, Brett A.
Mcdowell, Jennifer E.
Parker, David Alan
Keedy, Sarah
Keshavan, Matcheri S.
Tamminga, Carol A.
Pearlson, Godfrey D.
Gershon, Elliot S.
Ivleva, Elena Ivanovna
Abstract
A method and system for diagnosing an idiopathic psychosis patient and improving treatment targeting for that patient. Cognitive performance is measured on the patient. Pro- and anti-saccade signals are measured on the patient. Motor inhibition is measured on the patient. EEG signals are measured on the patient. Principal components analysis is applied to the measured signals and scales to determine the most significant features. The patient is evaluating on at least 11 dimensions of neuro-cognitive performance. A trained numerical taxonomy approach is used to classify the patient as belonging to a B-SNP psychosis Biotype and the patient's condition is categorized based on the classified Biotype. The B-SNIP psychosis Biotype is used to implement targeted treatment for an individual patient. The diagnostic algorithm is continuously re-trained using new cases and new laboratory tests to improve precision of B-SNIP psychosis Biotypes diagnosis and the accuracy of selecting treatments for individual patients.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
11.
COMPOSITIONS, SYSTEMS, KITS, AND METHODS FOR TREATING WOUNDS
Disclosed are compositions, kits, systems, and methods for treating or healing a wound. The compositions can include a carrier composition with a gas-entrapping material and a gas entrapped within the carrier composition.
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
This disclosure provides novel integrases for site-specific genetic engineering. Also provided are systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE) with the novel integrases.
Disclosed herein are example methods of assessing sleep disorders by detecting and tracking respiratory control instability by self-similarity analysis. A method of assessing sleep disorders of a patient includes receiving signals from the patient over a period of time while the patient is asleep, identifying a complex within the received signals, determining a ratio of a maximum envelope height to a minimum envelope height within the complex, determining a duration between a maximum envelope height of the complex and a subsequent maximum envelope of a subsequent complex, computing a convolution of a positive envelope and a rotated negative envelope of the complex, assessing a time location of a maximum distance between the positive envelope and the negative envelope, and determining a self-similarity of the received signals.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 35/04 - Antineoplastic agents specific for metastasis
15.
METHYLATION OF THE 5-ALPHA REDUCTASE 2 (SRD5A2) GENE
SRD5A2SRD5A2 as compared to a reference level; and administering to the identified subject a first therapy such as a combination therapy comprising a therapeutically effective amount of a 5-alpha reductase inhibitor and a selective estrogen receptor modulator.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present disclosure relates to bronchoscope devices and method of use for the visualization and surgical treatment of pulmonary conditions within the lungs of a patient. The bronchoscope assembly comprises a first working channel and a second working channel that respectively provide complementary functions for accessing the surgical site and a plurality of surgical applications.
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/015 - Control of fluid supply or evacuation
A61B 1/018 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor for receiving instruments
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
A61B 17/00 - Surgical instruments, devices or methods
17.
COMPOSITIONS AND METHODS OF TREATMENT WITH VECTORS HAVING REDUCED OR MODIFIED IMMUNOGENIC PROFILES
Adeno-associated viruses (AAVs) have been identified as ideal delivery vehicle for gene therapies and vaccines; however, AAV technology is limited by their immunogenic profile in humans. Disclosed herein are compositions and methods for reducing the immunogenicity of an AAV and other related nucleic acid delivery systems.
A system for increasing a frame rate of a dynamic image includes an input for receiving a set of consecutive image frames of a first dynamic image having a first plurality of image frames and a first frame rate. The system further includes a deformation encoding neural network coupled to the input and configured to derive at least one parameter characterizing dynamics of the set of consecutive image frames and to generate an interpolated image frame based on the at least one parameter, and a post-processing module coupled to the deformation encoding neural network and configured to receive one or more interpolated image frames from the deformation encoding neural network, to create a second plurality of image frames comprising the one or more interpolated image frames and the first plurality of image frames, and to generate a second dynamic image using the second plurality of image frames, the second dynamic image having a second frame rate higher than the first frame rate.
Provided herein are methods of preventing, suppressing, or treating cancer in a subject as well as methods of prolonging survival of a subject in need of cancer treatment. Such methods include administering (i) at least one immunotherapeutic agent, and (ii) a dual inhibitor of COX-2 and sEH; or (i) at least one immunotherapeutic agent, and (ii) an sEH inhibitor. The described methods further include optionally administering (iii) one or more chemotherapeutic agents, and/or (iv) a high omega-3 diet to the subject. Also provided herein are preventing, suppressing, or treating cancer in a subject as well as methods of prolonging survival of a subject in need of cancer treatment by administering (i) a high omega-3 diet or a high omega-6 diet, and optionally further including (ii) at least one immunotherapeutic agent.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
21.
COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTION
Tuberculosis (TB) remains a leading cause of death from infectious disease worldwide, in part due to the limited efficacy of currently available vaccine. Disclosed herein are compositions and methods for providing immunogenic protection against TB.
In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Drp1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.
Disclosed are compositions and methods for the treatment of skeletal muscle atrophy. In particular, the disclosure features a method of treating skeletal muscle atrophy with a composition comprising glyoxylate or pharmaceutically equivalent salts thereof in an individual. Additional methods and compositions for treating, mitigating, or preventing skeletal muscle atrophy are provided.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
Antigen-binding proteins including monoclonal antibodies (mAbs) against prothrombin, which bind to the open form of prothrombin and decrease conversion of prothrombin to thrombin are provided. Antibody fragments and conjugates are also provided. Anticoagulant pharmaceutical compositions based on the monoclonal antibodies against prothrombin and fragments and conjugates thereof are also provided, along with methods for treating and preventing blood clots and for reducing thrombin generation in patients.
The present invention relates to a surgical system for spinal stenosis decompression and methods thereof. The system design enables placement of the device through a contralateral approach that is advanced under direct visualization or fluoroscopic (X-Ray), or guided by 3D imaging for example, into areas of the spine including lumbar (low back), thoracic (mid and upper back) and cervical (neck). A tubular body with a cutting tool is advanced to separate tissue within the tubular body for removal and spinal decompression.
Provided herein are galloylated polyphenols useful in inhibiting thrombosis formation. Also provided herein are methods of treating or preventing thrombosis in a subject in need thereof that include administering to the subject a galloylated polyphenol, or a pharmaceutically acceptable salt thereof.
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
Disclosed are compositions comprising a lipid nanoparticle and a modified biomolecular corona. In some embodiments, the modified biomolecular corona comprises a fused cell-specific binding domain. In some embodiments, the modified biomolecular corona protein has been additionally modified such that it does not bind substantially to its natural receptor. In some embodiments, the fused cell-specific binding domain binds to a target cell.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
30.
COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES
Provided herein are galloylated polyphenols useful in inhibiting thrombosis formation. Also provided herein are methods of treating or preventing thrombosis in a subject in need thereof that include administering to the subject a galloylated polyphenol, or a pharmaceutically acceptable salt thereof.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Disclosed are methods of treating diseases or disorders mediated by dysregulated CDK4/6 and/or Pin 1 activity comprising co-administering a therapeutically effective amount of one or more CDK4/6 inhibitors, and a therapeutically effective amount of one or more Pin1 inhibitors, or a pharmaceutically acceptable salt or salts thereof
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention concerns the field of chimeric aptamers with high target specificity suitable for RNA based therapy. In particular, the present invention relates to the use of the chimeric aptamers for the preparation of a pharmaceutical composition for treating diseases characterized by altered DNA methylation.
Echocardiography deep learning and cardiovascular outcomes are described. An echocardiogram analysis module may include a deep learning model to generate a video output for an input echocardiogram video, the deep learning model comprising a convolutional neural network and at least one dense layer. The echocardiogram analysis module may further include a cardiac prediction generator to generate a cardiac prediction based on video outputs generated for a plurality of input echocardiogram videos of an echocardiogram study, the cardiac prediction comprising a measurement prediction or a classification prediction.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
34.
Echocardiography deep learning and cardiovascular outcomes
Echocardiography deep learning and cardiovascular outcomes are described. An echocardiogram analysis module may include a deep learning model to generate a video output for an input echocardiogram video, the deep learning model comprising a convolutional neural network and at least one dense layer. The echocardiogram analysis module may further include a cardiac prediction generator to generate a cardiac prediction based on video outputs generated for a plurality of input echocardiogram videos of an echocardiogram study, the cardiac prediction comprising a measurement prediction or a classification prediction.
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 20/40 - ScenesScene-specific elements in video content
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
35.
PROGRAMMABLE LIPID NANOPARTICLE DELIVERY VIA CORONA PROTEIN ENGINEERING
Disclosed are compositions comprising a lipid nanoparticle and a modified biomolecular corona. In some embodiments, the modified biomolecular corona comprises a fused cell-specific binding domain. In some embodiments, the modified biomolecular corona protein has been additionally modified such that it does not bind substantially to its natural receptor. In some embodiments, the fused cell-specific binding domain binds to a target cell.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A system, method, and apparatus to insert and remove a thermally activated vaginal pessary (102), by employing a nitinol core material that is integrated into the construction of the thermally activated vaginal pessary and configured to increase in radial size upon contact with body temperature by undergoing a configurational phase change in the underlying nitinol core material.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
37.
DIAGNOSTIC AND THERAPEUTIC METHODS USING HEME AS A BIOMARKER FOR CELLULAR AND TISSUE DAMAGE
Disclosed herein are methods of assessing cellular or tissue damage in a patient: methods of identifying a patient having sterile inflammation, methods of assessing sterile inflammation in a patient. methods of monitoring a patient undergoing a treatment with a therapeutic agent that causes cellular or tissue toxicity. methods of treating or preventing cellular or tissue damage in a patient in need thereof, methods of treating or preventing sterile inflammation in a patient in need thereof. and related uses and kits.
G01N 33/72 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood pigments, e.g. hemoglobin, bilirubin
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Provided herein are elastin-like polypeptides, endosomal escape peptides, and compounds comprising an elastin-like polypeptide chemically or recombinantly conjugated to one or more endosomal escape peptides. Also provided herein are compositions comprising a compound provided herein and an agent, methods of delivering an agent, and methods of treating or preventing a disease (e.g., a cardiovascular disease, a lung or respiratory disease, a musculoskeletal disease, a hematological disease, an immune disorder, an infectious disease, a genetic disease, cancer, a neurological disease, a psychiatric disorder, a metabolic disorder, or an inflammatory disease).
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
39.
PROTEOMIC BIOMARKERS FOR PREDICTING CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM
MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (USA)
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (USA)
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (USA)
Inventor
Zwicker, Jeffrey
Flaumenhaft, Robert
Gerzten, Robert
Karagkouni, Dimitra
Patell, Rushad
Vlachos, Ioannis
Schulman, Sol
Abstract
The present disclosure relates generally to methods for accurately predicting the risk of cancer-associated venous thromboembolism (CAT) and/or preventing CAT in cancer patients using proteomic biomarkers.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
Preferred embodiments relate to devices and methods for performing a lymphovenous bypass procedure. A coupling element is secured to tissue connected to at least one lymphatic channel of a patient and a vein or artery of the patient. An end of the lymphatic channel that extends through the coupling element is inserted into an open end of the vein or artery to deliver lymph fluid from the lymphatic channel into the vein or artery.
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
41.
REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA
The United States of America, as Represented by the Secretary, Department of Health and Human (USA)
President and Fellows of Harvard College (USA)
IIT Research Institute (USA)
Beth Israel Deaconess Medical Center, Inc. (USA)
Inventor
Solway, Julian
Dulin, Nickolai
Rosner, Marsha
Mutlu, Gokhan
Luci, Diane
Maloney, David
Park, Chan Young
Fredberg, Jeffrey
Mccormick, David
Krishnan, Ramaswamy
Abstract
Disclosed herein is a class of molecules termed remodilins that inhibit serum response factor (SRF). By inhibiting SRF, a number of downstream pathways can be targeted. The remodilins can be used to treat glaucoma, inhibit tumor cell growth, inhibit tumor metastasis, inhibit hypoxia-induced response, and/or reduce cellular metabolism.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
A61P 35/04 - Antineoplastic agents specific for metastasis
C07C 311/16 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
C07C 311/21 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 277/52 - Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
C07D 279/12 - 1,4-ThiazinesHydrogenated 1,4-thiazines not condensed with other rings
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 309/14 - Nitrogen atoms not forming part of a nitro radical
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Preferred embodiments relate to devices and methods for performing a lymphovenous bypass procedure. A coupling element is secured to tissue connected to at least one lymphatic channel of a patient and a vein or artery of the patient. An end of the lymphatic channel that extends through the coupling element is inserted into an open end of the vein or artery to deliver lymph fluid from the lymphatic channel into the vein or artery.
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 17/00 - Surgical instruments, devices or methods
43.
ELECTROPHORETIC MOBILITY SHIFT AS A MOLECULAR BEACON-BASED READOUT FOR MIRNA DETECTION
Aspects of the technology described herein relate to systems and techniques for detecting one or more nucleic acids comprising a target sequence of nucleotides, the method comprising incubating molecular beacons (MBs) and a concentration of nucleic acids, each comprising a sequence of nucleotides, wherein the molecular beacons are configured to generate a fluorescence signal when bound with the target sequence, performing electrophoresis by applying voltage, and determining, using the electrophoretic mobility shift of the MBs and nucleic acids during electrophoresis, the presence of the target sequence in the concentration of nucleic acids.
Provided herein are methods of treating a trauma patient, the method including: (a) administering a HDAC inhibitor to the trauma patient; and (b) administering a GRK2 inhibitor to the trauma patient, wherein the treatment prevents, reduces, or ameliorates the risk of an infection occurring after a traumatic event. In some cases, the infection is a respiratory infection, such as pneumonia. The HDAC inhibitor and/or the GRK2 inhibitor can be administered to the patient before, after, or before and after the traumatic event.
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
Most disease-associated genetic loci map to more than one disease or trait, suggesting they act through multiple cell types and tissues giving rise to complex disease phenotypes. This pervasive pleiotropy of human diseases presents a tremendous burden on identifying mediating mechanisms and therapeutic targets. Multiple metabolic risk haplotypes are associated with risk for metabolic diseases. However, whether a haplotype actually causes a disease and the mechanisms that cause the disease are unknown. Integration of phenotypic and transcriptional profiling in primary human cells allows for functional characterization of disease-associated genetic variants. Applicants have analyzed multiple risk haplotypes and determined the function of risk haplotypes involved in causation of specific metabolic phenotypes, such as type 2 diabetes and lipodystrophy. Methods of treatments are disclosed herein.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
The present disclosure provides chemical compounds such as benzimidazole carbamates that are inhibitors of DYRK1A kinase and are useful in treating, e.g., neurodegenerative diseases such as Alzheimer's disease, autoimmune diseases such as inflammatory bowel disease, osteoarthritis, and type-1 diabetes, and cancer (including brain tumors such as glioblastoma and neuroblastoma).
C07D 235/30 - Nitrogen atoms not forming part of a nitro radical
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61P 25/00 - Drugs for disorders of the nervous system
Embodiments disclosed herein provide a general, scalable, high-throughput, and high-resolution approach for experimental dissection of regulatory regions and driver nucleotides in the context of human biology and disease. Applicants present HiDRA, a novel high-resolution global screen for transcriptional regulatory activity in accessible chromatin regions, enabling high-efficiency, high-throughput, and high-resolution inference of regulatory activity.
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
48.
HETEROBIFUNCTIONAL SMALL MOLECULES THAT DEUBIQUITINYLATE AND STABILIZE TARGET PROTEINS BY RECRUITING USP7
Disclosed is a method and compounds for treating AMPK, cGAS, or ΔF508-CFTR mediated diseases, the method including administering one or more AMPK, cGAS, or CFTR DUBTACs to a subject who has an AMPK, cGAS, or ΔF508-CFTR -mediated disease, the AMPK, cGAS, or CFTR DUBTACs being heterobifunctional small-molecule compounds (or bivalent compounds in short) including an AMPK, cGAS, or CFTR ligand conjugated to a de-ubiquitination tag (such as a small-molecule ligand of USP7) via a linker, which would stabilize AMPK, cGAS, or CFTR. The AMPK, cGAS, or ΔF508-CFTR -mediated disease can be a disease resulting from AMPK, cGAS, or CFTR destabilization. The AMPK, cGAS, or ΔF508-CFTR-mediated disease can have reduced AMPK, cGAS, or CFTR expression relative to a wild-type tissue of the same species and tissue type. The disclosed bivalent compounds stabilize AMPK, cGAS, or CFTR by recruiting USP7.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61P 11/00 - Drugs for disorders of the respiratory system
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A soft robotic, 3D-printed simulator of heart function and disease has been designed to recreate the anatomy and function of specific people and patients with heart disease, for use personalized cardiovascular medicine. Using clinical imaging data, this system re-creates the anatomy of the left ventricle (the main pumping chamber of the heart) and of the aorta (the main blood vessel in the body). A soft robotic heart sleeve recapitulates the pumping action of the heart during normal physiology and disease. A soft robotic aortic sleeve can be added to the system to recapitulate disease of the aortic valve (separating the left ventricle and the aorta).
inter aliainter alia, methods for identifying subjects as being at risk of a cardiac event, ongoing myocardial injury, arrhythmias, and sudden cardiac death, and/or predicting positive response to anti-inflammatory drug therapies, e.g., in subjects who have inflammatory familial cardiac arrhythmias including arrhythmogenic cardiomyopathy (ACM) and Brugada syndrome (BrS), by detecting activated NFκB signaling in buccal cells. The methods can also include selecting and/or administering a treatment for the disease to the subject.
BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
BETH ISRAEL DEACONESS MEDICAL CENTER (USA)
Inventor
Demirci, Utkan
Ghiran, Ionita
Tasoglu, Savas
Davis, Ronald W.
Steinmetz, Lars
Durmus, Naside Gozde
Tekin, Huseyin Cumhur
Abstract
Magnetic cell levitation and cell monitoring systems and methods are disclosed. A method for separating a heterogeneous population of cells is performed by placing a microcapillary channel containing the heterogeneous population of cells in a magnetically-responsive medium in the disclosed levitation system and separating the cells by balancing magnetic and corrected gravitational forces on the individual cells. A levitation system is also disclosed, having a microscope on which the microcapillary channel is placed and a set of two magnets between which the microcapillary channel is placed. Additionally, a method for monitoring cellular processes in real-time using the levitation system is disclosed.
G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
B03C 1/32 - Magnetic separation acting on the medium containing the substance being separated, e.g. magneto-gravimetric-, magnetohydrostatic-, or magnetohydrodynamic separation
C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
C12Q 1/18 - Testing for antimicrobial activity of a material
G01N 15/00 - Investigating characteristics of particlesInvestigating permeability, pore-volume or surface-area of porous materials
G01N 15/06 - Investigating concentration of particle suspensions
G01N 15/1031 - Investigating individual particles by measuring electrical or magnetic effects
G01N 27/76 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids by investigating susceptibility
G01N 33/487 - Physical analysis of biological material of liquid biological material
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
52.
PROACTIVE DOCUMENT RETRIEVAL IN ELECTRONIC HEALTH RECORD NOTES
A method for predictive identification of relevant documents to clinical users during medical record entry includes receiving data characterizing a current clinical context, the data including a medical note input by the clinical user during one or more prior clinical tasks and processing the data characterizing the current clinical context to identify a set of one or more source documents relevant to a future clinical task of the clinical user from a plurality of source documents, wherein the processing is based at least in part on a model of clinical activity determined from prior activities of clinicians during medical record entry.
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G06F 16/16 - File or folder operations, e.g. details of user interfaces specifically adapted to file systems
G06F 16/2457 - Query processing with adaptation to user needs
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (Germany)
CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (Germany)
Inventor
Riella, Leonardo, V.
Greensmith, Robert
Kaminski, Michael
Riella, Cristian
Lape, Isadora T
Abstract
The invention features compositions and methods for multiplexed, point-of-care compatible CRISPR assays for precise genotyping of human APOL1 variants.
A method and apparatus for detecting compartment syndrome. The method includes passing, using a first pair of electrodes, a current through a region of muscle of a user; measuring, using a second pair of electrodes, one or more surface voltages; calculating, based on the one or more surface voltages, one or more measurements over a span of time; and determining, based on the one or more measurements over the span of time, whether the user is experiencing early muscle ischemia.
Disclosed are compounds that are irreversible small-molecule binders of OTUB1 (also known as Otubain 1), and bivalent compounds (e.g. bi-functional small molecule compounds) which recruit OTUB1 through the irreversible small-molecule binders of OTUB1 to de-ubiquitinylate and stabilize proteins such as AMPK, cGAS and CFTR. Also disclosed are methods for the treatment of AMPK, cGAS and CFTR-mediated diseases in a subject in need thereof. Also disclosed are methods for designing such compounds including irreversible small-molecule binders of OTUB1 and related bivalent compounds as de-ubiquitinase-targeting chimeras (DUBTACs) for targeted protein stabilization.
C07D 211/00 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
C07D 221/00 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
56.
MICROSPHERE DELIVERY APPARATUS FOR PROVIDING REAL-TIME MEASURING OF DELIVERED RADIOACTIVITY
A microsphere delivery apparatus providing real-time measuring of delivered radioactivity during procedures utilizing radioactive emitting microspheres wherein an administration housing includes a holder to receive a vial containing microspheres for delivery from a housing, a detector holder to receive a radiation detector and a delivery tube assembly for transporting fluid containing the microspheres.
A microsphere delivery apparatus providing real-time measuring of delivered radioactivity during medical procedures utilizing radioactive emitting microspheres wherein an administration housing includes a holder to receive a vial containing microspheres for delivery to a patient, a detector holder to receive a radiation detector and a delivery tube assembly for transporting fluid containing the microspheres.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
58.
USP2 INHIBITORS AND METHODS OF USING THE SAME FOR THE TREATMENT OF DISEASES
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
Inventor
Jin, Jian
Wei, Wenyi
Gu, Wei
Xiong, Yan
Hu, Xiaoping
Dang, Fabin
Yi, Jingjie
Abstract
Disclosed are small molecule ubiquitin carboxyl-terminal hydrolase 2 (USP2) inhibitors which display great potency in inhibiting cancer cell proliferation by elevating wild type P53 levels, reducing cyclin D levels or blocking ACE2 dependent virus from entering host cells by reducing ACE2 levels. The results indicate that these USP2 inhibitors have potential to be used in treating various diseases, including cancer and virus infection depending on ACE2.
Provided is the use of compounds of Formula I, as well as certain specific compounds, or a pharmaceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament to treat cancer, such as liver cancer (e.g. hepatocellular carcinoma) and lung cancer.
Provided is the use of compounds of Formula I, as well as certain specific compounds, or a pharmaceutically acceptable salt, solvate or derivative thereof, in the preparation of a medicament to treat cancer, such as liver cancer (e.g. hepatocellular carcinoma) and lung cancer.
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A method for magnetization prepared magnetic resonance imaging includes acquiring, using a magnetic resonance imaging (MRI) system, magnetic resonance (MR) data for at least two images of the region of interest of the subject. Each image of the at least two images is acquired using a different magnetization preparation or a different timing for magnetization preparation. The method further incudes generating the at least two images using the corresponding MR data and generating an image by comparing the at least two images. In some embodiments, the magnetization preparation is a T2 preparation and the at least two images are used to generate an image with signal representing water exchange. In some embodiments, the magnetization preparation is a velocity selective preparation and the at least two images are used to generate an image with signal representing perfusion.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
The present disclosure provides methods for modifying gluten polypeptides to produce gluten polypeptides with a reduced inflammatory potential, as well as modified plants and compositions comprising modified gluten polypeptides with a reduced inflammatory potential.
Methods for identifying bacterial species in biofluid samples (e.g., whole blood samples) are described. The methods rely on optical spectroscopy, and enable rapid detection and identification of bacteria directly from whole blood. Not only can LSS-based techniques detect and identify bacteria in biofluids such as whole blood, but that species-level identification can potentially be made based on a small number of bacterial cells, without the need for observing entire colonies or performing susceptibility testing. The methods may comprise illuminating the biofluid sample with input light, detecting scattered light produced by the biofluid sample in response to the illuminating, generating first data indicative of a measured scattering spectrum associated with the biofluid sample using the detected scattered light, and identifying whether at least one of the bacterial species is present in the biofluid sample using the first data.
G01N 21/51 - Scattering, i.e. diffuse reflection within a body or fluid inside a container, e.g. in an ampoule
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61P 35/04 - Antineoplastic agents specific for metastasis
66.
SYNTHESIS OF CORE 2 O-SIALYL LEWIS-X POLYSACCHARIDES
C07H 1/00 - Processes for the preparation of sugar derivatives
C07H 5/10 - Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to sulfur, selenium, or tellurium to sulfur
C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
C07H 15/26 - Acyclic or carbocyclic radicals, substituted by hetero rings
C07H 23/00 - Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
67.
GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventor
Flynn, Ryan Alexander
Goodman, Brian
Lawlor, Ciaran
Bisaria, Namita
Cummings, Richard D.
Wei, Mohui
Bertozzi, Carolyn R.
Abstract
The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
The present disclosure features a probe that includes an optical sensor. The optical sensor includes a plurality of particles (e.g., cells) that include a ligand receptor coupled to an optical label (e.g., a molecular sensor, e.g., a GPCR fused to a fluorescent protein). The plurality of particles is immobilized on the probe, e.g., on a lens or optical fiber attached to or incorporated within the probe, e.g., at or near a distal end of the probe.
In certain aspects, the disclosure relates to devices and methods for treating wounds wherein an acetylcholinesterase inhibitor is delivered to a wound to promote wound healing. In further aspects, metrifonate can be delivered to the wound by time release from a wound dressing. In further aspects a sequence of wound dressings can be applied to the wound to treat different phases of wound healing.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The present invention relates to a flexible surgical system for endoscopic spinal decompression and methods thereof. Various methods of accessing the epidural space with this instrument are described. The system design enables placement of the device through several approaches. It is then advanced under direct visualization or fluoroscopic (X-Ray), for example, into areas of the spine including lumbar (low back), thoracic (mid and upper back) and cervical (neck). The pathologies encroaching upon the spinal space can then be visualized wherein the epidural membrane can optionally be displaced to further aid in visualization. The membrane can be used to protect regions of tissue adjacent the site to tissue removal.
A61B 1/313 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for introducing through surgical openings, e.g. laparoscopes
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances
A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements
A61B 1/32 - Devices for opening or enlarging the visual field, e.g. of a tube of the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 90/30 - Devices for illuminating a surgical field, the devices having an interrelation with other surgical devices or with a surgical procedure
71.
SYSTEMS AND METHODS FOR IMPROVING SLEEP AND OTHER INDICATIONS, INCLUDING TREATING ANXIETY
The present disclosure generally relates, in certain embodiments, to light-based treatments. In some case, a subject having or at risk for a condition such as insomnia can be treated, e.g., with light, such as green light. Other conditions include sleep disorders such as sleep apnea and other indications. In some cases, the light that is administered to the subject may be green light, or the light may have a characteristic wavelength only in a wavelength range between 510 nm and 550 nm with a bandwidth no larger than 20 nm full-width-half-maximum. Other embodiments described herein are generally directed to systems for treating such conditions, kits for treating such conditions, or the like.
A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
In certain aspects, the disclosure relates to devices and methods for treating wounds wherein an acetylcholinesterase inhibitor is delivered to a wound to promote wound healing. In further aspects, metrifonate can be delivered to the wound by time release from a wound dressing. In further aspects a sequence of wound dressings can be applied to the wound to treat different phases of wound healing.
A61L 15/18 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
In certain aspects, the disclosure relates to a recombinant nucleic acid molecule (e.g. RNA molecule) encoding one or more polypeptides selected from the group consisting of chitinase- 3-like protein 1 (CHI3L1), a fibroblast growth factor (FGF), interleukin-2 ORF7 (IL- 2 ORF7), interleukin-2 (IL-2), an interleukin- 17 (IL-17) protein, and an IL-17 receptor, wherein the recombinant RNA molecule comprises at least one chemical modification. Cells, pharmaceutical compositions and wound dressings comprising one or more of the recombinant nucleic acid molecules are also disclosed. Methods of promoting wound healing in a subject are further disclosed.
Provided herein are methods of identifying and/or diagnosing an active lupus nephritis (LN) flare in a subject, the method comprising obtaining a sample from the subject; isolating cells from the urine sample; and determining a level of expression of calcium/calmodulin dependent protein kinase IV (CaMK4), IL-23, IL-17 receptor, and/or arginase 1, wherein an increased level of expression of CaMK4, IL-23, and/or IL-17 receptor as compared to a control or a decreased level of expression of arginase 1 as compared to a control indicates an active lupus nephritis (LN) flare in the subject.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
75.
Conserved region T cell vaccines for coronavirus and methods of use
The present disclosure relates to compositions and methods of treating cancer in a subject in need thereof, relating to a specific non-coding RNA (ncRNA)-S Phase Early RNAs (SPEARs) or inhibitors thereof.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6804 - Nucleic acid analysis using immunogens
Systems and methods are provided for producing diffusion-weighted images of a subject using a magnetic resonance imaging (MRI) system. The method includes performing a stimulated echo preparation module using non-selective radio-frequency (RF) pulses designed to induce a stimulated echo, performing an acquisition module that includes a multi-slice acquisition of MR data in the presence of diffusion gradients, and reconstructing the diffusion-weighted images of the subject from the MR data.
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
G01R 33/483 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy
G01R 33/54 - Signal processing systems, e.g. using pulse sequences
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
G01R 33/567 - Image enhancement or correction, e.g. subtraction or averaging techniques gated by physiological signals
78.
COMPOSITIONS AND METHODS FOR REGULATING PROCOAGULANT ACTIVITY AND THROMBOSIS
The present invention relates to methods of treating thrombotic disorders and hypercoagulation, including disorders related to COVID-19 and cancer. TMEM16 inhibitors are disclosed which inhibit development and progression of procoagulant endothelial cell dysfunction. Such inhibitors can be administered to a patient singly or in combination, and treating patients with a combination of complimentary TMEM16 inhibitors can result in beneficial, synergistic effects.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
The present invention provides methods for treating a stiffened joint in a subject that comprise administering relaxin, e.g., a PEGylated relaxin-2, to the subject. The relaxin may be administered intra-articularly as a sustained release formulation. The present invention also provides sustained release formulations in the form of a hydrogel for administering polypeptides that are covalently attached to a polymer, e.g., PEG.
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61M 3/00 - Medical syringes, e.g. enemataIrrigators
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
80.
ELECTRIC IMPEDANCE MYOGRAPHY FOR CHARACTERIZING AND TRACKING BLADDER AND PELVIC FLOOR DISORDERS
Devices and methods for evaluating and treating neurogenic bladder (NB) are disclosed. In some embodiments, a probe may include microneedles for gently puncturing the bladder detrusor tissue of a test subject. The microneedles may non-invasively collect a series of electric impedance myography (EIM) measurements to evaluate the condition of the bladder and assist in diagnosis. In some embodiments, the probe may provide information regarding the tissue's structural and biophy siological condition, in a real-time, quantitative, and objective manner. In some embodiments, the probe may assist in identifying optimal treatment (e.g., Botox or biomaterials injection) sites for NB by providing real-time results.
This disclosure relates to PEGylated selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide or polysaccharide and a polyethylene glycol (PEG) moiety. In some embodiments, the disclosure relates to uses of the PEGylated glycopeptides as anti-inflammatory, anti-thrombotic, or anti-metastatic agents.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
84.
PROTACS WITH TRANSCRIPTION FACTOR TARGETING MOIETIES
Transcription factors (TFs) represent a major class of therapeutic targets for the treatment of human diseases including cancer. Although the biological function and even crystal structure of many TFs have been clearly elucidated, there is still no viable approach to target the majority of TFs, thus rendering them undruggable for decades. PROTACs (PROteolysis TArgeting Chimeras) have emerged as a powerful tool for the pharmaceutical development since the effect of PROTACs largely relies on engineered protein-protein interaction to aid the degradation of targets by the ubiquitin-proteasome system (UPS). The present disclosure provides a DNA-PROTAC platform for targeted degraders of individual TFs of interest. These DNA based Transcription Factor targetting PROTACS (or “TF-PROTACS”) may provide specificity to TF degradation based on the conserved DNA-binding motifs of respective TFs. We have synthesized two series of VHL-based TF-PROTACs lead compounds and measured their degradation of proteins in transcription factors: NF-κB-PROTAC (or dNF-κB) and E2F-PROTAC (or dE2F). NF-κB-PROTAC efficiently degrades p65 protein subunit in the NF-κB transcription factors in cells. E2F-PROTAC efficiently degrades E2F1 protein subunit in the E2F transcription factor in cells. Taken together, this design provides a generalizable platform of TF-PROTACs to achieve selective degradation of TFs in cells.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
85.
COMPOSITIONS AND METHODS FOR IDENTIFYING AND MODULATING THROMBOTIC CONDITIONS IN A CANCER PATIENT
The present invention relates to compositions and methods for identifying at-risk patients and modulating thrombotic conditions in a cancer patient. Embodiments provided herein include a method of determining risk for a thrombotic event in a cancer patient comprising: detecting in a sample of a patient with cancer elevated levels of PPIA, PDIA3 and at least one of EIF5A, EIF4H, EIF4a3, UBE2N, UBE2L3, UBE2I, and HSP70.
The Board of Trustees of the Leland Stanford Junior University (USA)
Inventor
Flynn, Ryan Alexander
Goodman, Brian
Lawlor, Ciaran
Bisaria, Namita
Cummings, Richard D.
Wei, Mohui
Bertozzi, Carolyn R.
Abstract
The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.
A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
87.
METHODS AND COMPOSITIONS RELATED TO NON-CODING VARIANTS FOR THE PREDICTION OF RESPONSE TO CANCER IMMUNOTHERAPY
The present disclosure relates to compositions and methods for the detection of 3' UTR somatic mutations and/or variants for use as prognostic assay for response to cancer immunotherapy. The present disclosure allows for the use of one or more non-coding mutations alone or in combination with non-coding mutations in genic (e.g. 5' UTR, introns, promoters) or intergenic loci, as well as coding variants, for the prediction of response to cancer immunotherapy.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present disclosure provides anti-Tn antibodies (e.g., BaGs6 and/or Remab6) having superior specificity for Tn antigen on cancer cells. Also provided herein, are nucleic acids, vectors, or vector sets that encode the anti-Tn antibody.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (USA)
Inventor
Chaikof, Elliot, L.
Liu, Jian
Stancanelli, Eduardo
Xu, Yongmei
Abstract
e.ge.g., heparin oligomers of Formula (I)), pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof, compounds thereof, polymer conjugates thereof, oligosaccharide conjugates thereof, and methods of synthesis. Also provided herein are pharmaceutical compositions, surface coatings, devices, and kits including a heparin oligomer provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. Also provided herein are methods of using a heparin oligomer (or a related compound, conjugate, or pharmaceutical composition thereof) as provided herein, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for treating disease or reducing or inhibiting thrombus formation.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
The present disclosure provides methods and compositions for the diagnosis and treatment of IgA nephropathy. Detection and quantitation of serum IgM levels is performed using an IgA molecule including a GalNAc-alpha 1-Ser/Thr antigen. ELISAs and flow cytometry based methods are claimed. In the examples, Asialo-BSM microbeads are used.
Disclosed are immunogenic compositions and vaccines containing rationally designed coronavirus Spike proteins and polynucleotides encoding the same that can be administered to treat or inhibit a coronavirus infection. The compositions and vaccines can also be used to produce anti-coronavirus antibodies (e.g., broadly neutralizing anti-coronavirus antibodies), which can also be used for prophylactic or therapeutic purposes in the treatment of a coronavirus infection.
The present disclosure describes a computerized system for a method that includes: accessing brain images of a patient, e.g., a patient who has been diagnosed with a psychotic disorder, or at high risk for developing the psychotic disorder, wherein the brain images comprise a first set of images depicting a brain structure of the patient and a second set of images encoding a brain function of the patient; generating masks based on morphing a symptom region of an atlas to the first set of images, wherein the atlas is based on a cohort of participants with the psychotic disorder; identifying treatment regions based on applying the one or more masks to the second set of images, wherein the treatment regions are specific to the patient and the symptom; and causing at least one transcranial magnetic stimulation (TMS) therapy session targeting the one or more treatment regions to be administered.
This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
A method for generating a magnetic resonance (MR) image of a subject includes receiving an MR image of the subject reconstructed from undersampled MR data of the subject and providing the low resolution MR image of the subject to an image sharpness neural network. The image sharpness neural network can be implemented without an upsampling layer. The image sharpness neural network may be trained using a set of loss functions including an L1 Fast Fourier Transform (FFT) loss function. The method may further include generating an enhanced resolution MR image of the subject with increased sharpness based on the MR image of the subject using the image sharpness neural network.
11 Fast Fourier Transform (FFT) loss function. The method may further include generating an enhanced resolution MR image of the subject with increased sharpness based on the MR image of the subject using the image sharpness neural network.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Provided herein are methods of preventing, mitigating, decreasing, reversing and/or treating Arrhythmogenic Cardiomyopathy (ACM) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, a compounds of Formula II, or a compound of Formula III (I) (II), (III) wherein R1, R2, R3, n, R4, R4a, R5, m, R6, R7, and p are as defined herein.
Provided herein are methods of preventing, mitigating, decreasing, reversing and/or treating Arrhythmogenic Cardiomyopathy (ACM) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, a compounds of Formula II, or a compound of Formula III (I) (II), (III) wherein R1, R2, R3, n, R4, R4a, R5, m, R6, R7, and p are as defined herein.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
The present application provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the compound of Formula (I), and methods of using the compound of Formula (I) for treating viral infections and inhibiting thromobosis are also provided.
The present application provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions containing the compound of Formula (I), and methods of using the compound of Formula (I) for treating viral infections and inhibiting thromobosis are also provided.
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided are compositions and methods for alleviating symptoms or treating gluten-related diseases. In some embodiments, the compositions include colostrum from cows that are immunized with gluten or partially digested gluten.
A shape memory adhesive material for adhering and contracting wounds, particularly diabetic wounds, to facilitate their closure and healing. The shape memory adhesive is pre-stretched and dried to provide an adhesive structure with a pre-programmed strain, wherein the adhesive is capable of rapid robust adhesion followed by predictive contraction upon contact with a wet surface. According to preferred embodiments, the shape memory adhesive material includes a combination of one or more hydrophilic polymers or copolymers, one or more amine coupling group, and one or more cross linkers.
